Skip to content

Depression: all studies

Page 100 of 1,034: studies 991 to 1,000 of 10,336, newest first. Back to the depression overview

Research

Can Esketamine Become a Viable Alternative for Treating Treatment-Resistant Depression in Ecuador?

European Psychiatry April 1, 2025 E. Pazmiño, K. Armas

IntroductionTreatment-resistant Depression (TRD) nowadays it is consider a public health problem. Studies had demonstrate that TRD has higher prevalence of psychiatric comorbid conditions, twice the utilization of outpatient health care resources, 3 times the number of inpatient bed-days, and 23% higher all-cause mortality. Esketamine, the S-enantiomer of ketamine, has been recently approved...

Esketamine and Ketamine use in the Adolescent Population for Treatment Resistent Depression: A Systematic Review

European Psychiatry April 1, 2025 G. Chen, Y. Li

IntroductionKetamine is widely recognized for its dissociative anesthetic properties, particularly in procedural sedation and severe pain management among children, adolescents, and young adults. Despite its noted applications, research investigating ketamine’s impact on mood and suicidality within this specific demographic remains limited. This retrospective review seeks to address this gap by...

Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)

Journal of Personalized Medicine April 1, 2025 Marco Di, M. Pepe, Giacomo D’andrea et al. 18 citations

Background. Treatment-resistant depression (TRD) is a prevalent, high-burden disorder. Esketamine nasal spray (ESK-NS) has been approved for, T.R.D.; and efficacy has been observed in both clinical trials and real-world studies. However, observations integrating patients’ perspective on this treatment are limited. This multicentric Italian study explored experiences with ESK-NS in TRD patients,...

Response to Ketamine Therapy in Anxious and Non-Anxious Major Depressive Disorder: A Meta-Analysis of Clinical Trials

European Psychiatry April 1, 2025 Ilídio Oliveira, A. L. Stephany, M. L. Geremias et al.

Introduction Anxious depression (AxD) as an independent diagnostic has been controversial, with many suggesting it as a transient state and others highlighting evidence of a worse outcome, severity, and increased suicide risk. The International Classification of Diseases (ICD-11) lists a related concept under 6A73, Mixed depressive and anxiety disorder. Previous literature on ketamine’s...

Psilocybin: Systematic review of its use in the treatment of depression

European Psychiatry April 1, 2025 P. Andres-Olivera, Janis V. de la Iglesia, E. Dominguez-Alvarez et al.

Introduction Psilocybin, a psychedelic compound, has shown potential in treating depression, especially in cases resistant to conventional treatments. This study systematically reviews the scientific literature to assess its efficacy and safety. Objectives The main objective of this study is to evaluate the therapeutic effects of psilocybin for the treatment of depressive disorder through a...

Minorities’ diminished psychedelic returns: Depression, suicide, distress, and serious mental illness

Drug Science, Policy and Law April 1, 2025 Sean M. Viña 4 citations

Although there is growing support for the protective effects of psychedelics on mental health, recent evidence finds racial and ethnic minorities gain fewer benefits. This paper aims to test whether the disparate mental health outcomes associated with psychedelic use extend across multiple racial and ethnic groups, including non-Hispanic Whites, Blacks, Asians, and Hispanics. In order to...

DOI: 10.1177/20503245251337357 (opens in new tab) Mental illness Depression economics Mental distress Clinical psychology +1

Examining what works for whom and how in mindfulness-based cognitive therapy (MBCT) for recurrent depression: moderated-mediation analysis in the PREVENT trial.

The British Journal of Psychiatry April 1, 2025 Jesus Montero-Marin, Verena Hinze, Shannon Maloney et al. 4 citations

Personalised management of recurrent depression, considering individual patient characteristics, is crucial. This study evaluates the potentially different mediating role of mindfulness skills in managing recurrent depression using mindfulness-based cognitive therapy (MBCT) among people with varying depression severity. Data from the Prevention of Depressive Relapse or Recurrence (PREVENT)...

DOI: 10.1192/bjp.2024.178 (opens in new tab) Full text (opens in new tab) Recurrent depression Depression severity Mindfulness skills Mindfulness-based cognitive therapy +1

Revitalizing Minds: Exploring the Transformative Power of Mindfulness-Based Nursing Interventions on Depression and Resilience in Oncology Patients-A Quasiexperimental Approach.

International Journal of Nursing Practice April 1, 2025 Ateya Megahed Ibrahim, Soma Ibrahim Ali, Mai El-Ghareap Hassan El-Metwally Omar 2 citations

This study evaluated the impact of mindfulness-based nursing interventions (MBNIs) on reducing depression and enhancing resilience in oncology patients. Oncology patients face high levels of depression and weakened resilience, which significantly reduces their quality of life, affects their ability to adhere to treatment and worsens health outcomes. Additional stressors linked to the diagnosis,...

DOI: 10.1111/ijn.70005 (opens in new tab) Full text (opens in new tab) Depression Mindfulness interventions mindfulness Specialized nursing interventions Mindfulness practices +9

Evaluation of mindfulness-based interventions for pain, anxiety, and depression in spinal cord injury patients: A systematic review and meta-analysis.

Clinical neurology and neurosurgery April 1, 2025 Alison Reilly, Ahmad Sharif, Ojas Bhagra et al. 4 citations

Rehabilitative measures following spinal cord injury (SCI) typically fail to mitigate the psychological symptoms that might heighten pain levels. Mindfulness-based interventions (MBI) have been proposed to address such concerns. We aim to review the literature on MBI used for pain, anxiety, and depression in SCI. A systematic literature search for studies using MBI in patients with pain and...

Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression.

Journal of Psychopathology and Clinical Science April 1, 2025 Shabnam Hossein, Mary L Woody, Benjamin Panny et al. 3 citations

Ketamine has shown promise in rapidly improving symptoms of depression and most notably treatment-resistant depression (TRD). However, given the heterogeneity of TRD, biobehavioral markers of treatment response are necessary for the personalized prescription of intravenous ketamine. Heterogeneity in depression can be manifested in discrete patterns of functional connectivity (FC) in default...

DOI: 10.1037/abn0000951 (opens in new tab) Full text (opens in new tab) Depression treatment Brain connectivity Mood patterns Personalized medicine +1